IL-17A Influences Essential Functions of the Monocyte/Macrophage Lineage and Is Involved in Advanced Murine and Human Atherosclerosis

Atherosclerosis is a chronic inflammatory disease. Lesion progression is primarily mediated by cells of the monocyte/macrophage lineage. IL-17A is a proinflammatory cytokine, which modulates immune cell trafficking and is involved inflammation in (auto)immune and infectious diseases. But the role of IL-17A still remains controversial. In the current study, we investigated effects of IL-17A on advanced murine and human atherosclerosis, the common disease phenotype in clinical care. The 26-wk-old apolipoprotein E–deficient mice were fed a standard chow diet and treated either with IL-17A mAb (n = 15) or irrelevant Ig (n = 10) for 16 wk. Furthermore, essential mechanisms of IL-17A in atherogenesis were studied in vitro. Inhibition of IL-17A markedly prevented atherosclerotic lesion progression (p = 0.001) by reducing inflammatory burden and cellular infiltration (p = 0.01) and improved lesion stability (p = 0.01). In vitro experiments showed that IL-17A plays a role in chemoattractance, monocyte adhesion, and sensitization of APCs toward pathogen-derived TLR4 ligands. Also, IL-17A induced a unique transcriptome pattern in monocyte-derived macrophages distinct from known macrophage types. Stimulation of human carotid plaque tissue ex vivo with IL-17A induced a proinflammatory milieu and upregulation of molecules expressed by the IL-17A–induced macrophage subtype. In this study, we show that functional blockade of IL-17A prevents atherosclerotic lesion progression and induces plaque stabilization in advanced lesions in apolipoprotein E–deficient mice. The underlying mechanisms involve reduced inflammation and distinct effects of IL-17A on monocyte/macrophage lineage. In addition, translational experiments underline the relevance for the human system.

[1]  R. Flavell,et al.  Transforming growth factor-beta signaling in t cells promotes stabilization of atherosclerotic plaques through an interleukin-17 dependent pathway , 2014 .

[2]  T. Ueland,et al.  Increased Systemic and Local Interleukin 9 Levels in Patients with Carotid and Coronary Atherosclerosis , 2013, PloS one.

[3]  R. Flavell,et al.  Transforming Growth Factor–β Signaling in T Cells Promotes Stabilization of Atherosclerotic Plaques Through an Interleukin-17–Dependent Pathway , 2013, Science Translational Medicine.

[4]  P. Libby,et al.  Local proliferation dominates lesional macrophage accumulation in atherosclerosis , 2013, Nature Medicine.

[5]  P. Cohen,et al.  IL-17 Stimulates Differentiation of Human Anti-Inflammatory Macrophages and Phagocytosis of Apoptotic Neutrophils in Response to IL-10 and Glucocorticoids , 2013, The Journal of Immunology.

[6]  N. Danchin,et al.  Circulating levels of interleukin-17 and cardiovascular outcomes in patients with acute myocardial infarction. , 2013, European heart journal.

[7]  M. Fujimoto,et al.  Potential roles of interleukin-17A in the development of skin fibrosis in mice. , 2012, Arthritis and rheumatism.

[8]  Breanne N. Gjurich,et al.  The IL-17A/IL-17RA Axis Plays a Proatherogenic Role via the Regulation of Aortic Myeloid Cell Recruitment , 2012, Circulation research.

[9]  Y. Iwakura,et al.  Interleukin-17A Deficiency Accelerates Unstable Atherosclerotic Plaque Formation in Apolipoprotein E-Deficient Mice , 2012, Arteriosclerosis, thrombosis, and vascular biology.

[10]  HiroyukiTsutsui,et al.  Interleukin-17A Deficiency Accelerates Unstable Atherosclerotic Plaque Formation in Apolipoprotein E-Deficient Mice , 2012 .

[11]  A. Quyyumi,et al.  Role of Interleukin 17 in Inflammation, Atherosclerosis, and Vascular Function in Apolipoprotein E–Deficient Mice , 2011, Arteriosclerosis, thrombosis, and vascular biology.

[12]  D. Rader,et al.  Suppressed monocyte recruitment drives macrophage removal from atherosclerotic plaques of Apoe-/- mice during disease regression. , 2011, The Journal of clinical investigation.

[13]  K. Moore,et al.  Macrophages in the Pathogenesis of Atherosclerosis , 2011, Cell.

[14]  T. Junt,et al.  Th17 Cells, Not IL-17+ γδ T Cells, Drive Arthritic Bone Destruction in Mice and Humans , 2011, The Journal of Immunology.

[15]  Shuang Chen,et al.  IL-17A Is Proatherogenic in High-Fat Diet-Induced and Chlamydia pneumoniae Infection-Accelerated Atherosclerosis in Mice , 2010, The Journal of Immunology.

[16]  Kristina M. Little,et al.  Cxc Chemokine Ligand 4 Induces a Unique Transcriptome in Monocyte-derived Macrophages Address Correspondence and Reprint Requests To , 2022 .

[17]  K. Ley,et al.  Blockade of Interleukin-17A Results in Reduced Atherosclerosis in Apolipoprotein E–Deficient Mice , 2010, Circulation.

[18]  P. Teeling,et al.  Differential expression of interleukin‐17 family cytokines in intact and complicated human atherosclerotic plaques , 2010, The Journal of pathology.

[19]  C. Gleissner,et al.  CXCL4 Downregulates the Atheroprotective Hemoglobin Receptor CD163 in Human Macrophages , 2010, Circulation Research.

[20]  D. Böckler,et al.  Inhibition of IL-17A Attenuates Atherosclerotic Lesion Development in ApoE-Deficient Mice1 , 2009, The Journal of Immunology.

[21]  Yong Chen,et al.  CorrigendumCorrigendum to “The Th17/Treg imbalance in patients with acute coronary syndrome” [Clin. Immunol. 127 (2008) 89–97] , 2009 .

[22]  Claudia Jakubzick,et al.  Regulation of the migration and survival of monocyte subsets by chemokine receptors and its relevance to atherosclerosis. , 2009, Arteriosclerosis, thrombosis, and vascular biology.

[23]  C. Uyttenhove,et al.  Loss of SOCS3 expression in T cells reveals a regulatory role for interleukin-17 in atherosclerosis , 2009, The Journal of experimental medicine.

[24]  Yuhong Yang,et al.  T-bet is essential for encephalitogenicity of both Th1 and Th17 cells , 2009, The Journal of experimental medicine.

[25]  K. Ley,et al.  Immune and inflammatory mechanisms of atherosclerosis (*). , 2009, Annual review of immunology.

[26]  J. Pober,et al.  Interleukin-17 and Interferon-γ Are Produced Concomitantly by Human Coronary Artery–Infiltrating T Cells and Act Synergistically on Vascular Smooth Muscle Cells , 2009, Circulation.

[27]  Stephen W. Waldo,et al.  Heterogeneity of human macrophages in culture and in atherosclerotic plaques. , 2008, The American journal of pathology.

[28]  Yong Chen,et al.  The Th17/Treg imbalance in patients with acute coronary syndrome. , 2008, Clinical immunology.

[29]  E. Fisher,et al.  Rapid regression of atherosclerosis: insights from the clinical and experimental literature , 2008, Nature Clinical Practice Cardiovascular Medicine.

[30]  S. Gordon.  The macrophage: Past, present and future , 2007, European journal of immunology.

[31]  M. Shin,et al.  Synergistic Proinflammatory Effects of the Antiviral Cytokine Interferon-&agr; and Toll-Like Receptor 4 Ligands in the Atherosclerotic Plaque , 2007, Circulation.

[32]  M. Gawaz,et al.  Platelet-associated LIGHT (TNFSF14) mediates adhesion of platelets to human vascular endothelium , 2007, Thrombosis and Haemostasis.

[33]  S. Haulon,et al.  PPARgamma activation primes human monocytes into alternative M2 macrophages with anti-inflammatory properties. , 2007, Cell metabolism.

[34]  R. D. Hatton,et al.  IL-17 family cytokines and the expanding diversity of effector T cell lineages. , 2007, Annual review of immunology.

[35]  Alberto Mantovani,et al.  Transcriptional Profiling of the Human Monocyte-to-Macrophage Differentiation and Polarization: New Molecules and Patterns of Gene Expression1 , 2006, The Journal of Immunology.

[36]  Pablo Tamayo,et al.  Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[37]  Nitin Jain,et al.  Rank-invariant resampling based estimation of false discovery rate for analysis of small sample microarray data , 2005, BMC Bioinformatics.

[38]  H. Methe,et al.  Expansion of Circulating Toll-Like Receptor 4–Positive Monocytes in Patients With Acute Coronary Syndrome , 2005, Circulation.

[39]  E. Fisher,et al.  Emigration of monocyte-derived cells from atherosclerotic lesions characterizes regressive, but not progressive, plaques. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[40]  S. Akira,et al.  Lack of Toll-like receptor 4 or myeloid differentiation factor 88 reduces atherosclerosis and alters plaque phenotype in mice deficient in apolipoprotein E. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[41]  Jae K. Lee,et al.  Local-pooled-error test for identifying differentially expressed genes with a small number of replicated microarrays , 2003, Bioinform..

[42]  M. Fishbein,et al.  Toll-Like Receptor-4 Is Expressed by Macrophages in Murine and Human Lipid-Rich Atherosclerotic Plaques and Upregulated by Oxidized LDL , 2001, Circulation.

[43]  N. Kadowaki,et al.  Subsets of Human Dendritic Cell Precursors Express Different Toll-like Receptors and Respond to Different Microbial Antigens , 2001, The Journal of experimental medicine.

[44]  C. Gleissner,et al.  Expression of IL-17A in human atherosclerotic lesions is associated with increased inflammation and plaque vulnerability , 2010, Basic Research in Cardiology.

[45]  R. Yao,et al.  The Th 17 / Treg imbalance in patients with acute coronary syndrome , 2008 .

[46]  嶋田 光恵.  IL-6 secretion by human pancreatic periacinar myofibroblasts in response to inflammatory mediators , 2002 .